CD274 and cutaneous squamous cell carcinoma: Cemiplimab, approved by the US FDA between 2018 and 2021 for cutaneous squamous cell carcinoma, basal cell carcinoma and NSCLC with high PD‐L1 expression [232, 233], demonstrates distinct toxicity patterns.